OPTION AND STOCK PURCHASE AGREEMENT ------------------------------------------------------------------------ by and among BROADCAST HOLDINGS, INC. G. CABELL WILLIAMS, III ALLIED CAPITAL FINANCIAL CORPORATIONOption and Stock Purchase Agreement • March 31st, 1998 • Radio One Inc • Radio broadcasting stations • Maryland
Contract Type FiledMarch 31st, 1998 Company Industry Jurisdiction
EXHIBIT 10.7 OPTION AND STOCK PURCHASE AGREEMENT BETWEEN THE COMPANY AND CARACAS VIVA VISION, S.A. AND ITS SHAREHOLDERS OPTION AND STOCK PURCHASE AGREEMENT BETWEEN AND AMONGOption and Stock Purchase Agreement • August 21st, 1997 • Wireless Cable & Communications Inc • Cable & other pay television services • Utah
Contract Type FiledAugust 21st, 1997 Company Industry Jurisdiction
RECITALS --------Option and Stock Purchase Agreement • March 5th, 1998 • Westminster Capital Inc • Communications services, nec
Contract Type FiledMarch 5th, 1998 Company Industry
EXHIBIT 10.8 JULY 24, 1997 AMENDMENT TO OPTION AND STOCK PURCHASE AGREEMENTOption and Stock Purchase Agreement • August 21st, 1997 • Wireless Cable & Communications Inc • Cable & other pay television services
Contract Type FiledAugust 21st, 1997 Company Industry
ARTICLE 1Option and Stock Purchase Agreement • March 5th, 1998 • Westminster Capital Inc • Communications services, nec • California
Contract Type FiledMarch 5th, 1998 Company Industry Jurisdiction
Development, option and STOCK PURCHASE AGREEMENT BY AND AMONG alexion Pharmaceuticals, INC., caelum biosciences, Inc., The Sellers, And fortress biotech, inc., as the representative DATED AS OF January 30, 2019Option and Stock Purchase Agreement • May 10th, 2019 • Fortress Biotech, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 10th, 2019 Company Industry JurisdictionThis development, option and STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of January 30, 2019, by and among Alexion Pharmaceuticals, Inc., a Delaware Corporation (the “Buyer”), Caelum Biosciences, Inc., a Delaware corporation (the “Company”), the holders of the securities of the Company listed on Exhibit A and signatories hereto (collectively, the “Sellers”), and Fortress Biotech, Inc. (“Fortress”), in its capacity as the Representative.